Identification of a potential biomarker for FABP4 inhibition: the power of lipidomics in pre-clinical drug testing
Helmholtz Zentrum München and Boehringer Ingelheim jointly identify biomarker for diabetes-relevant protein
The fatty acid binding protein 4 (FABP4) contributes to the development of insulin resistance and atherosclerosis in mice. Lack of FABP4 protects against the development of insulin resistance associated with genetic or diet-induced obesity in mice. The FABP4 small-molecule inhibitor BMS309403 has demonstrated efficacy in mouse models for type 2 diabetes mellitus and atherosclerosis, resembling phenotypes of mice with FABP4 deficiency. However, despite the therapeutically attractive long-term effects of FABP4 inhibition, an acute biomarker for drug action is lacking. We report the identification of a potential biomarker for acute in vivo FABP4 inhibition that is applicable for further investigations and can be implemented in simple and fast-flow injection mass spectrometry assays. In addition, this approach can be considered a proof-of-principle study that can be applied to other lipid-pathway targeting mechanisms.
Core statement Pressemitteilung:
The cooperation between the Helmholtz Zentrum München and Boehringer Ingelheim has produced its first results: the two partners have jointly identified a biomarker that now allows for the testing of active substances on a diabetes-related protein. The results, which have now been published in the Journal of Biomolecular Screening, prove the added value of collaboration between the pharmaceutical industry and academia in researching new drugs for the treatment of diabetes and atherosclerosis (Journal of Biomolecular Screening).
1 Records found.